Handa Pharmaceuticals Inc (6620) Stock Price & Analysis
6620 Stock Chart & Stats
- Day’s Range
- TWD 90.50 - TWD 110.50
- 52-Week Range
- TWD 64.10 - TWD 155.00
- Previous Close
- TWD 100.50
- Volume
- N/A
- Average Volume (3M)
- 2.94M
- Market Cap
- TWD 17.35B
- Enterprise Value
- TWD 7.88B
- Total Cash (Recent Filing)
- TWD 3.73B
- Total Debt (Recent Filing)
- TWD 41.03M
- Price to Earnings (P/E)
- 37.0
- Beta
- 1.04
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jul 06, 2026
- Dividend Yield
- 1.98%
6620 FAQ
What was Handa Pharmaceuticals Inc’s price range in the past 12 months?
What is Handa Pharmaceuticals Inc’s market cap?
When is Handa Pharmaceuticals Inc’s upcoming earnings report date?
How were Handa Pharmaceuticals Inc’s earnings last quarter?
Is Handa Pharmaceuticals Inc overvalued?
Does Handa Pharmaceuticals Inc pay dividends?
What is Handa Pharmaceuticals Inc’s EPS estimate?
How many shares outstanding does Handa Pharmaceuticals Inc have?
What happened to Handa Pharmaceuticals Inc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Handa Pharmaceuticals Inc?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Handa Pharmaceuticals Inc
Handa Pharmaceuticals, Inc. operates as a specialized drug company, concentrating its efforts on creating and advancing new medications for diverse health issues across both the United States and China. The firm currently offers Quetiapine XR, a treatment for Schizophrenia, as well as Dexlansoprazole DR capsules. Beyond its existing portfolio, Handa is actively cultivating a robust pipeline of therapies. This includes their cutting-edge ONCORE drug delivery platform, engineered to boost patient adherence and improve the safety of tyrosine kinase inhibitor oncology drugs. Other significant projects encompass a 505(b)(2)NDA therapeutic agent, Tascenso ODT for managing multiple sclerosis, and the oncology candidates HND-033 and HND-027. Furthermore, the company's development initiatives feature HND-004, designed for diabetic patients; HND-032, intended to aid in smoking cessation; and HND-026, a gastrointestinal medication. Founded in 2014, Handa Pharmaceuticals, Inc. has its main corporate headquarters situated in Tainan City, Taiwan.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Fang-Yu Liu
- Employees
- 15
- Website
- www.handapharma.com.tw
- Address
- No.23, Nanke 3rd Road, Tainan City, TQ, 744094, TW
Handa Pharmaceuticals Inc (6620) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 3 | 11 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 3 | 0 | 9 |

